SIGA Technologies Aug 4, earnings report and notes from the call.
With the U.S. declaration of a national health emergency the drug could soon be more widely available under an EUA. The company itself does not have its own production facilities but instead relies on third-party production sources. This means the company’s CAP X is very low and they can scale up production if required.
If the monkey pox outbreak warrants the company can produce up to 500,000 courses a year with the current capacity. In pill form, the drug is taken over a period of two weeks and this is a course. The price for each course for international customers Is $900-$1000 per course. In the US it is $300-$400. Pricing differs depending on the size of the order. Should the company deliver 500,000 courses in a single year it’s revenue from Tecovirimat would be $500 million in that year. Revenue (TTM) was 139.4 million as per last reporting, so the growth potential for the company and its share price is significant. Especially if ( as is now predicted by many health professionals) Monkeypox becomes endemic globally.
Link to SIGA Technologies earnings report.
Submitted August 05, 2022 at 05:01PM by 1Avidobserver
via reddit https://ift.tt/plOYGKJ